Form 8-K Prime Medicine, Inc. For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Medifast launches Trilivy, replacing its Optavia brand
- Adobe has received a takeover approach by a Big Tech company - Betaville
TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
July 8, 2026 12:30 PM EDTTD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).
The analyst comments "PRME announced a positive binding arbitration resolution with BEAM over PM647 in AATD, confirming PM647 is in PRMEs field with no monetary damages. This removes a key investor overhang and clears the path for a Q3:26 filing, with initial data in 2027. We continue to view PRME as undervalued for the platforms potential. Buy. PRME announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, with the tribunal declaring that PM647 falls within PRMEs... More
